» Articles » PMID: 38383750

Comorbidity in Myasthenia Gravis: Multicentric, Hospital-based, and Controlled Study of 178 Italian Patients

Abstract

Background: Myasthenia gravis (MG) is an autoimmune disorder with fluctuating weakness that causes significant disability and morbidity. Comorbidities may influence the course of MG, particularly in specific subgroups. The aim of this study is to investigate the frequency of comorbidities in MG patients compared to healthy controls (HC) and to evaluate their distribution according to age at disease onset, sex, and disease severity.

Methods: MG patients attending the University Hospital "Paolo Giaccone" in Palermo and "SS Annunziata" Hospital in Chieti were enrolled; HC were enrolled from the general population. Non-parametric statistics and logistic regression were used to assess the association of specific comorbidities according to age at disease onset, sex, disease subtypes, and severity of the disease.

Results: A total of 356 subjects were included in the study: 178 MG patients (46% F; median age 60 years [51-71]) and 178 sex- and age-matched HC (46% F, median age 59 years [50-66]). Overall, 86% of MG patients and 76% of HC suffered from comorbidities, and MG patients had a higher number of comorbidities compared to HC. Patients with late-onset suffered from more comorbidities than those with early-onset MG. Hypertension was more common in male patients with MG, while thymic hyperplasia, osteoporosis, and autoimmune diseases were more common in females. Respiratory disorders and thymoma were more common in patients with more severe disease (p < 0.05 for all comparisons).

Conclusion: MG patients, particularly those with late onset, showed a higher prevalence of comorbidities than HC. Assessment of comorbidities in MG is an essential issue to identify the appropriate treatment and achieve the best management.

Citing Articles

Unusual presentations of myasthenia gravis and misdiagnosis.

Oguz-Akarsu E, Lazrak S, Gullu G, Dinc Y, Saridas F, Karli N Sci Rep. 2025; 15(1):7516.

PMID: 40032968 PMC: 11876431. DOI: 10.1038/s41598-025-91470-6.


Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes.

Jin L, Zou Z, Wang Q, Zeng W, Jiang Q, Chen J Ther Adv Neurol Disord. 2025; 18:17562864251319656.

PMID: 39974170 PMC: 11837134. DOI: 10.1177/17562864251319656.


Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study.

Zhu G, Zhou H, Wang W, Ma Y, Nie X, Qi W Ther Adv Neurol Disord. 2025; 18():17562864241311127.

PMID: 39839222 PMC: 11748066. DOI: 10.1177/17562864241311127.


Optimal time for the addition of non-corticosteroid immunosuppressants in myasthenia gravis: a single-center retrospective study in China.

Ma J, Chen D, Yi F, Song J, Luo S, Zhong H Front Neurol. 2024; 15:1474508.

PMID: 39574506 PMC: 11580010. DOI: 10.3389/fneur.2024.1474508.


Epilepsy and Myasthenia Gravis: A Case Series.

Oyarzun I, Hernandez G, Sala-Padro J, Morandeira F, Casasnovas C, Falip M Brain Sci. 2024; 14(9).

PMID: 39335366 PMC: 11430324. DOI: 10.3390/brainsci14090870.


References
1.
Herishanu Y, Rosenberg P . Letter: beta-Blockers and myasthenia gravis. Ann Intern Med. 1975; 83(6):834-5. DOI: 10.7326/0003-4819-83-6-834. View

2.
Meriggioli M, Sanders D . Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8(5):475-90. PMC: 2730933. DOI: 10.1016/S1474-4422(09)70063-8. View

3.
Iacono S, Di Stefano V, Costa V, Schiro G, Lupica A, Maggio B . Frequency and Correlates of Mild Cognitive Impairment in Myasthenia Gravis. Brain Sci. 2023; 13(2). PMC: 9953757. DOI: 10.3390/brainsci13020170. View

4.
Chou C, Huang M, Lan W, Kong S, Kuo C, Chou I . Prevalence and risk of thyroid diseases in myasthenia gravis. Acta Neurol Scand. 2020; 142(3):239-247. DOI: 10.1111/ane.13254. View

5.
Alekseeva T, Kreis O, Gavrilov Y, Valko P, Weber K, Valko Y . Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis. J Neurol. 2019; 266(8):2027-2034. DOI: 10.1007/s00415-019-09374-1. View